Texas Ozempic Blindness Attorney

As a Texas medical doctor and Texas Ozempic blindness attorney, I am writing this article to highlight the link between Ozempic use and a blindness condition known as NAION.

In July 2024, a medical study found an increased risk of an eye disease that can cause blindness in patients on semaglutide, the key ingredient in Ozempic and Wegovy.

Medical Study Links Ozempic and NAION

The medical study published in JAMA Ophthalmology by researchers at Massachusetts Eye and Ear found an increase in NAION cases in patients on Ozempic and Wegovy.

What is the Risk of Blindness?

The researchers found 17 cases of NAION in diabetic patients at their hospital who were taking semaglutide, compared to 6 cases in diabetic patients who were not taking semaglutide. The study linked semaglutide with a 4.28-fold increased risk of NAION.

What is NAION?

NAION is short for Non-Arteritic Anterior Ischemic Optic Neuropathy, and it is an “eye stroke” that occurs when there is a lack of blood flow that damages the optic nerve.

The optic nerve is the connection between the brain and the eye. When the optic nerve is damaged due to NAION, patients may experience sudden, painless loss of vision in one eye. NAION causes swelling of the optic nerve. This optic nerve swelling improves with time, but the vision loss does not improve.

No Treatment for NAION Blindness

The optic nerve damage from NAION is permanent, and usually incurable. The vision loss may worsen over the next few weeks, but it does not get better.

NAION Signs & Symptoms

• Sudden painless loss of vision in one eye
• Vision loss in one or both eyes
• Darkened or shaded area of the visual field
• “Shadow” or “Curtain” over the upper or lower half of the visual field
• Blindness

Diabetes Is a Risk-Factor for Blindness

About 6,000 people are diagnosed with NAION every year. It is most common in people who are over 50 years old, especially people with risk-factors like type-2 diabetes, cardiovascular disease, obstructive sleep apnea, high blood pressure, and use of certain medications.

Case Reports and Additional Evidence

A case report published in Neuro-Ophthalmology described a 73-year-old man with type 2 diabetes, obesity, and hypertension who developed bilateral NAION after significant weight loss and postural hypotension while on semaglutide.

This case suggests that rapid physiological changes, such as weight loss or blood pressure fluctuations, may contribute to NAION risk in susceptible individuals.

Additionally, the FDA’s adverse event reporting system has noted NAION cases linked to semaglutide, though the data is not yet sufficient to establish causality.

Ozempic Litigation 2025 Update

The federal multidistrict litigation (MDL) for Ozempic, titled “In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation” (MDL No. 3094), was established in February 2024. The MDL has over 1,997 pending cases in the Eastern District of Pennsylvania.

The litigation alleges that Novo Nordisk failed to adequately warn about severe gastrointestinal side effects, such as gastroparesis, ileus, and bowel obstruction, linked to Ozempic and other GLP-1 drugs. The first bellwether trials are not expected until 2027.

NAION Cases Consolidated in New Jersey State Court

In New Jersey state courts, lawsuits are focused on NAION-related injuries. One of the first such cases was filed on April 15, 2025, alleging that a New Jersey resident developed NAION after using Ozempic, blaming the condition to inadequate warnings by Novo Nordisk.

More than 20 New Jersey residents filed vision-loss suits in April 2025, leading to the consolidation of these blindness claims into a single state litigation. These state actions operate under the Multicounty Litigation (MCL) framework, which coordinates similar cases and may align discovery efforts with the federal MDL.

The vision loss lawsuits are in the early stages, with no settlements or trials, and ongoing research continues.

Eligibility for an Ozempic and NAION Blindness Lawsuit

Financial compensation may be available via an Ozempic and NAION lawsuit settlement for people who received name-brand Ozempic injections and suffered from NAION.

Dr. Shezad Malik Law Firm is investigating Ozempic and NAION lawsuits against Novo Nordisk for people throughout the United States who have developed NAION injuries that could have been prevented.

To determine if you or a loved one qualifies for an Ozempic and NAION Lawsuit, submit information for review, and we will evaluate the circumstances of your potential claim. There are no fees or expenses paid unless a settlement or lawsuit payout is received.

Contact Dr Shezad Malik Law Firm Now for NAION Blindness

If you or a loved one uses Ozempic or Wegovy for weight loss or diabetes treatment and has developed NAION, contact the attorneys at Dr. Shezad Malik Law Firm to learn more about your legal rights. You can speak with one of our representatives by calling 214-390-3189 or by filling out the case evaluation form on this page.

Our law firm’s principal office is in Dallas, Texas. Dr. Shezad Malik Law Firm represents clients in dangerous drug and dangerous medical device lawsuits nationwide.